Weber Alan W Has Decreased Saratoga Investment (SAR) Holding, Sorrento Therapeutics (SRNE) Sentiment Is 1.38

June 20, 2017 - By Adrian Erickson

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The company has market cap of $141.20 million. The Firm is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. It currently has negative earnings. The Company’s primary therapeutic focus is oncology, including the treatment of chronic cancer pain.

Weber Alan W decreased Saratoga Investment Corp (SAR) stake by 66.93% reported in 2016Q4 SEC filing. Weber Alan W sold 35,000 shares as Saratoga Investment Corp (SAR)’s stock declined 7.04%. The Weber Alan W holds 17,293 shares with $356,000 value, down from 52,293 last quarter. Saratoga Investment Corp now has $123.39 million valuation. The stock declined 1.27% or $0.27 reaching $20.95 per share. About 9,776 shares traded. Saratoga Investment Corp (NYSE:SAR) has risen 31.19% since June 20, 2016 and is uptrending. It has outperformed by 14.49% the S&P500.

Since January 1, 0001, it had 10 insider purchases, and 1 insider sale for $158,916 activity.

About 906,428 shares traded or 0.54% up from the average. Sorrento Therapeutics Inc (SRNE) has declined 73.31% since June 20, 2016 and is downtrending. It has underperformed by 90.01% the S&P500.

Wildcat Capital Management Llc holds 6.31% of its portfolio in Sorrento Therapeutics Inc for 2.80 million shares. Venbio Select Advisor Llc owns 1.46 million shares or 1.44% of their US portfolio. Moreover, Cormorant Asset Management Llc has 1.26% invested in the company for 1.91 million shares. The Georgia-based Vident Investment Advisory Llc has invested 0.08% in the stock. Gagnon Securities Llc, a New York-based fund reported 11,116 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: